Literature DB >> 23226571

Roles for crk in cancer metastasis and invasion.

Masumi Tsuda1, Shinya Tanaka.   

Abstract

The Crk family of adaptors is implicated in regulating various biological and pathological processes such as cell proliferation, adhesion, migration, invasion, phagocytosis, and survival. A large number of studies have shown that Crk plays an important role in aggressive and malignant behaviors of human cancers. In immunohistochemical analyses and gene-expression profiles, enhanced expression of Crk has been identified in adenocarcinomas of lung, breast, and stomach and in sarcomas and glioma. Overexpression of Crk in tumor cells induces the prominent tyrosine phosphorylations of scaffolding molecules such as p130(Cas) and paxillin through Src family tyrosine kinases and stimulates the activation loop of intracellular signalling, ultimately contributing to the increased motility and aggressive potential of cancer cells. Crk proteins thus are not simply conduits for intracellular signal transduction but also can control the amplitude of signalling. This review summarizes the significance of Crk and its mediated signaling assemblies, particularly in regulating tumor metastasis and invasion, and discusses the possibilities that they are potential cancer therapeutic targets.

Entities:  

Keywords:  Crk adaptor protein; human cancer; invasion; metastasis

Year:  2012        PMID: 23226571      PMCID: PMC3513794          DOI: 10.1177/1947601912458687

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  53 in total

Review 1.  Functions of the adapter protein Cas: signal convergence and the determination of cellular responses.

Authors:  A H Bouton; R B Riggins; P J Bruce-Staskal
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

Review 2.  Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold.

Authors:  David Chodniewicz; Richard L Klemke
Journal:  Biochim Biophys Acta       Date:  2004-07-05

3.  Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.

Authors:  Joerg Kumbrink; Kathrin H Kirsch
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

4.  Overexpression of dedicator of cytokinesis I (Dock180) in ovarian cancer correlated with aggressive phenotype and poor patient survival.

Authors:  Fung Zhao; Michelle K Y Siu; LiLi Jiang; Kar Fai Tam; Hextan Y S Ngan; Xiao-Feng Le; Oscar G W Wong; Esther S Y Wong; Hoi Yan Chan; Annie N Y Cheung
Journal:  Histopathology       Date:  2011-12       Impact factor: 5.087

5.  Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma.

Authors:  Jinna Shi; Shan Wang; Eryang Zhao; Lei Shi; Xin Xu; Ming Fang
Journal:  J Oral Pathol Med       Date:  2010-01-28       Impact factor: 4.253

6.  Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts.

Authors:  R B Birge; J E Fajardo; C Reichman; S E Shoelson; Z Songyang; L C Cantley; H Hanafusa
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

7.  p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.

Authors:  Anna C Cunningham-Edmondson; Steven K Hanks
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-12-07

8.  p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity.

Authors:  Michael K Wendt; Jason A Smith; William P Schiemann
Journal:  J Biol Chem       Date:  2009-10-12       Impact factor: 5.157

9.  Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/Akt survival pathway in tamoxifen resistant breast cancer cells.

Authors:  Shefali Soni; Bor-Tyh Lin; Avery August; Robert I Nicholson; Kathrin H Kirsch
Journal:  J Cell Biochem       Date:  2009-05-15       Impact factor: 4.429

10.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

View more
  25 in total

1.  17p13.3 microduplication including CRK leads to overgrowth and elevated growth factors: A case report.

Authors:  Rohan K Henry; Caroline Astbury; Constantine A Stratakis; Scott E Hickey
Journal:  Eur J Med Genet       Date:  2016-09-12       Impact factor: 2.708

2.  Crk adaptor proteins mediate actin-dependent T cell migration and mechanosensing induced by the integrin LFA-1.

Authors:  Nathan H Roy; Joanna L MacKay; Tanner F Robertson; Daniel A Hammer; Janis K Burkhardt
Journal:  Sci Signal       Date:  2018-12-11       Impact factor: 8.192

3.  Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.

Authors:  Sushil Kumar; Viralkumar Davra; Alison E Obr; Ke Geng; Teresa L Wood; Mariana S De Lorenzo; Raymond B Birge
Journal:  Oncoimmunology       Date:  2017-09-27       Impact factor: 8.110

4.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

5.  Mouse and human CRKL is dosage sensitive for cardiac outflow tract formation.

Authors:  Silvia E Racedo; Donna M McDonald-McGinn; Jonathan H Chung; Elizabeth Goldmuntz; Elaine Zackai; Beverly S Emanuel; Bin Zhou; Birgit Funke; Bernice E Morrow
Journal:  Am J Hum Genet       Date:  2015-02-05       Impact factor: 11.025

6.  The role of CRKL in breast cancer metastasis: insights from systems biology.

Authors:  Abderrahim Chafik
Journal:  Syst Synth Biol       Date:  2015-09-10

7.  Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.

Authors:  Qingliang Shen; Veer S Bhatt; Inna Krieger; James C Sacchettini; Jae-Hyun Cho
Journal:  Medchemcomm       Date:  2018-02-01       Impact factor: 3.597

8.  Drugs for solid cancer: the productivity crisis prompts a rethink.

Authors:  Daniel Rösel; Jan Brábek; Pavel Veselý; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2013-06-26       Impact factor: 4.147

9.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

10.  NFAT1 is highly expressed in, and regulates the invasion of, glioblastoma multiforme cells.

Authors:  Xinxin Tie; Sheng Han; Lingxuan Meng; Yunjie Wang; Anhua Wu
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.